wip Pharma #pharma #idw #transformers

In today’s headlines: pharmaphorum.com/news #news #pharma #lifesciences #pharmanews #pharmaindustry

The pharma industry often prioritizes profit over truly rigorous proof for medications. It's a system where financial gain can overshadow scientific validation. #pharma #science

Concerns around compounded GLP-1 peptides are high due to unregulated sourcing and lack of oversight. It's a stark contrast to the scrutiny COVID vaccines underwent before injection. #pharma #safety

A Cochrane review examines how pharmaceutical promotion shapes prescribing appropriateness, volume and cost. https://www.mattheneus.com/editorial/cochrane-pharmaceutical-promotion-prescribing-appropriateness-cost-review-2026-10-09 #HTA #Pharma #HealthEconomics

DAY 5; CHAINSAW
#Maccadam #pharma #goretober #fanart #transformers

Moderna outlined its COVID-era manufacturing lessons and how the biotech works with CDMOs at CPHI Milan this week

www.pharmaceutical-technology.com/analyst-comm...

#pharma #biotech #manufacturing #CPHI #CDMO

Up and Down the Ladder: Job Changes.. the latest comings and goings.. statnews.com/pharmalot/20... #pharma #biotech #jobs #Genentech #Novartis #BioMarin #Roche

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about a setback for Argenx, Lilly suits over copycat versions of an obesity drug, and more news.. statnews.com/pharmalot/20... #pharma #obesity #Argenx #Teva #Viatris #Lilly #DrReddys

Novartis’ President of Biomedical Research, Fiona Marshall, on what it would take for big pharma to go all in on longevity.

Link as first comment.

#longevity #Novartis #biomedicalresearch #pharma #FionaMarshall

Poland’s conditional Tevimbra recommendation shows how comparator updates shape reimbursement. https://www.mattheneus.com/editorial/aotmit-tevimbra-tislelizumab-conditional-reimbursement-risk-sharing-2026-10-07 #HTA #Pharma #RegulatoryAffairs

French reassessment highlights how outcomes evidence can reshape reimbursement decisions. https://www.mattheneus.com/editorial/has-zimino-levosimendan-reassessment-insufficient-clinical-benefit-2026-08-26 #HTA #EvidenceSynthesis #Pharma

Signal or noise? > Prula-cel Shows Early Promise in Lupus - The Medicine
Maker >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #pharma #healthcare #biotech #pharmaceutical

#FridayFeeling #FridayVibes #FridayMotivation #fridaymorning #Friday #4040rec #medicalsales #marketing #marketaccess #leadership #recruitment #talentacquisition #UKJobs #medicalequipment #medicalconsumables #medicaldevices #pharma #healthcare #biotech #medtech #lifesciences #healthcaresales

I love their tension with eachother #TYMA #Tyrest #Pharma #transformers #MTMTE

France's early access refusal for Pyrukynd highlights how evidence and access criteria shape rare-disease decisions. #HTA #RegulatoryAffairs #Pharma https://www.mattheneus.com/editorial/has-pyrukynd-mitapivat-sickle-cell-early-access-refusal-riseup-2026-10-01

Signal or noise? > Reusing data could cut R&D costs and greatly
increase gene editing’s reach: ARM - BioSpace >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #biotech #pharma #competitivemarketing

What does it take to turn AI pilots in pharma into real world results? Don't miss our talk at #ddpwest26 discussing how to turn isolated experiments into a repeatable workflow for ongoing insights.

RSVP: www.dnanexus.com/unifying-omi...

#DataScience #Pharma #EnterpriseAI #DNAnexus

By 2023, Novo Nordisk, a drug company, became Europe's most valuable publicly traded company, surpassing LVMH, the luxury empire. A Nobel laureate's detour led to a drug now outranking the continent's grandest luxury brands. #pharma #business